nephrogenic systemic fibrosis (nsf) and gadolinium-based contrast media
Clicks: 271
ID: 130578
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
271 views
34 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #19 of 77 articles by views in annales pharmaceutiques francaises
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Nephrogenic systemic fibrosis (NSF), unknown before March 1997 and first described in 2000, is a systemic disorder characterised by widespread tissue fibrosis. The first known case occurred in 1997, after the use of gadolinium-based contrast agents (GBCAs) at high doses in patients with renal failure had become routine. An overwhelming majority occurred within weeks to months after injection of a GBCA. This note comprises guidelines on the prevention of NSF.
| Reference Key |
ngoya2013southnephrogenic
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;P.S. Ngoya;Z Vawda;J.W Lotz |
| Journal | annales pharmaceutiques francaises |
| Year | 2013 |
| DOI |
10.4102/sajr.v17i3.277
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.